Brief: Cyteir Therapeutics Reports Third Quarter 2021 Financial Results
12/11/2021 12:43
Nov 12 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS
AND PROVIDES BUSINESS HIGHLIGHTS
* Q3 LOSS PER SHARE $0.33
* CYTEIR THERAPEUTICS - ENDED QUARTER WITH APPROXIMATELY
$200
MILLION IN CASH TO CONTINUE TO ADVANCE PIPELINE AND TO FUND
OPERATIONS THROUGH 2023
Source text for Eikon: ID:nBw1BG40a
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile